Pruritus

Dermatology·MeSH: Pruritus

Prevalence

30.0 / 100K

14 drugs in development·11 companies·4 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
desloratadine	PERRIGO Co plc (PRGO)
doxepin	Amneal Pharmaceuticals, Inc. (AMRX)
korsuva / kapruvia	Tvardi Therapeutics, Inc. (TVRD)
zenrelia	Elanco Animal Health Inc (ELAN)

Phase 3(4)

Drug	Company
difelikefalin	Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS)
fexofenadine	Sanofi (SNY)
Fexofenadine	Sanofi (SNY)
sna-120	SIENNA BIOPHARMACEUTICALS, INC. (SNNA)

Phase 2(1)

Drug	Company
Tricalm Hydrogel	Clearside Biomedical, Inc. (CLSDQ)

Preclinical(2)

Drug	Company
Anti-itch Product	Journey Medical Corp (DERM)
tp-2021	TITAN PHARMACEUTICALS INC (TTNP)

Phase 2/Phase 3(1)

Drug	Company
nalbuphine hcl er	Trevi Therapeutics, Inc. (TRVI)

Phase 4(2)

Drug	Company
Fexofenadine HCL and pseudoephedrine HCL	Sanofi (SNY)
Triamcinolone acetonide 0.1% cream	Clearside Biomedical, Inc. (CLSDQ)

BioSniper tracks 14 drugs in development for Pruritus across 11 companies.

There are 4 clinical trials targeting Pruritus tracked by BioSniper.

The estimated prevalence of Pruritus is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.